BlackRock Group’s BioSpecifics Technologies Corp. BSTC Stock Holding History

BlackRock Group’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$237K	Hold	4,250	–	–	﹤0.01%	2614
2016 Q3	$194K	Hold	4,250	–	–	﹤0.01%	2639
2016 Q2	$170K	Hold	4,250	–	–	﹤0.01%	2636
2016 Q1	$148K	Sell	4,250 -4,592	-52%	-$169K	﹤0.01%	2654
2015 Q4	$380K	Hold	8,842	–	–	﹤0.01%	2301
2015 Q3	$385K	Sell	8,842 -2,490	-22%	-$134K	﹤0.01%	2301
2015 Q2	$585K	Sell	11,332 -1,737	-13%	-$74.1K	﹤0.01%	2212
2015 Q1	$512K	Hold	13,069	–	–	﹤0.01%	2190
2014 Q4	$505K	Buy	+13,069	New	+$499K	﹤0.01%	2229

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

BlackRock Group's BSTC Position: Q4 2016 in Review

BlackRock Group held its BioSpecifics Technologies Corp. (BSTC) position steady in Q4 2016 at 4,250 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #2614.

BlackRock Group first reported a position in BSTC in Q4 2014 and has held it in 9 quarters since. The position peaked at $585K in Q2 2015. 96 funds tracked by Wall St. Rank hold BSTC as of Q4 2016.

BlackRock Group held 4,250 shares of BioSpecifics Technologies Corp. worth $237K as of Q4 2016.
BlackRock Group left its BioSpecifics Technologies Corp. share count unchanged in Q4 2016.
BioSpecifics Technologies Corp. made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2614 holding.
BlackRock Group first reported a position in BioSpecifics Technologies Corp. in Q4 2014 and has held it in 9 quarters since.
BlackRock Group's BioSpecifics Technologies Corp. position peaked at $585K in Q2 2015.
96 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.